

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 March 2025 (20.03.2025)



(10) International Publication Number
WO 2025/059417 A1

(51) International Patent Classification:

C07D 207/06 (2006.01) C07D 403/06 (2006.01)
C07D 211/26 (2006.01) C07D 405/04 (2006.01)
C07D 241/04 (2006.01) C07D 487/08 (2006.01)
C07D 265/30 (2006.01) A61P 1/04 (2006.01)
C07D 401/12 (2006.01)

(21) International Application Number:

PCT/US2024/046548

(22) International Filing Date:

13 September 2024 (13.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/583,193 15 September 2023 (15.09.2023) US
63/687,191 26 August 2024 (26.08.2024) US


(71) Applicant: MORPHIC THERAPEUTIC, INC. [US/US];
35 Gatehouse Drive, A2, Waltham, Massachusetts 02451
(US).

(72) Inventors: HARRISON, Bryce; c/o Morpnic Therapeu-
tic, Inc., 35 Gatehouse Drive, A2, Waltham, Massachusetts
02451 (US). BABAOGU, Kerim; c/o Morpnic Therapeu-
tic, Inc., 35 Gatehouse Drive, A2, Waltham, Massachusetts

02451 (US). BUCKMELTER, Alex; c/o Morpnic Thera-
peutic, Inc., 35 Gatehouse Drive, A2, Waltham, Massachu-
setts 02451 (US). BURSAVICH, Matthew; c/o Morpnic
Therapeutic, Inc., 35 Gatehouse Drive, A2, Waltham, Mass-
achusetts 02451 (US). CHEN, Yang-Ting; c/o Morpnic
Therapeutic, Inc., 35 Gatehouse Drive, A2, Waltham, Mass-
achusetts 02451 (US). DOWLING, James E.; c/o Morpnic
Therapeutic, Inc., 35 Gatehouse Drive, A2, Waltham, Mass-
achusetts 02451 (US). LIN, Fu-Yang; c/o Morpnic Thera-
peutic, Inc., 35 Gatehouse Drive, A2, Waltham, Massachu-
setts 02451 (US). LIPPA, Blaise; c/o Morpnic Therapeu-
tic, Inc., 35 Gatehouse Drive, A2, Waltham, Massachusetts
02451 (US). MCTEAGUE, Thomas Andrew; c/o Mor-
pnic Therapeutic, Inc., 35 Gatehouse Drive, A2, Waltham,
Massachusetts 02451 (US). MONDAL, Prolay; c/o Mor-
pnic Therapeutic, Inc., 35 Gatehouse Drive, A2, Waltham,
Massachusetts 02451 (US). MONROY, Meghan; c/o Mor-
pnic Therapeutic, Inc., 35 Gatehouse Drive, A2, Waltham,
Massachusetts 02451 (US). QIAO, Qi; c/o Morpnic Ther-
apeutic, Inc., 35 Gatehouse Drive, A2, Waltham, Massa-
chusetts 02451 (US). LELOUP, Nadia; c/o Morpnic Ther-
apeutic, Inc., 35 Gatehouse Drive, A2, Waltham, Massa-
chusetts 02451 (US). TROAST, Dawn; c/o Morpnic Ther-
apeutic, Inc., 35 Gatehouse Drive, A2, Waltham, Massa-
chusetts 02451 (US). ZHONG, Cheng; c/o Morpnic Ther-
apeutic, Inc., 35 Gatehouse Drive, A2, Waltham, Massa-

(54) Title: INHIBITING HUMAN INTEGRIN $\alpha 4 \beta 7$

FIGURE I



(57) Abstract: Disclosed are compounds for and methods of treating or preventing a disease or condition responsive to inhibition human $\alpha 4 \beta 7$ integrin by administering to a patient in need thereof a compound disclosed herein, such as a compound of Formula (I) or Formula (VI), or a pharmaceutically acceptable salt thereof. Many diseases and conditions can be treated by administration of the compounds disclosed here-in such as compounds of Formula (I), including, for example, inflam-matory bowel disease (IBD), ulcerative colitis, or Crohn's disease.

WO 2025/059417 A1

[Continued on next page]

chusetts 02451 (US). **HICKEY, Eugene**; c/o Schrödinger, Inc., 1540 Broadway, 24th Floor, New York, New York 10036 (US). **HOUANG, Evelyne**; c/o Schrödinger, Inc., 1540 Broadway, 24th Floor, New York, New York 10036 (US). **KONZE, Kyle**; c/o Schrödinger, Inc., 1540 Broadway, 24th Floor, New York, New York 10036 (US). **RAFI, Salma**; c/o Schrödinger, Inc., 1540 Broadway, 24th Floor, New York, New York 10036 (US). **SVENSSON, Mats**; c/o Schrödinger, Inc., 1540 Broadway, 24th Floor, New York, New York 10036 (US).

(74) **Agent: WOOD, Dan L.** et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))